Researcher Profile

Researcher Profile

Raymond Hohl, MD, PhD

Raymond Hohl, MD, PhD

University Professorship in Oncology, Department of Medicine
Professor, Department of Pharmacology
Scientific Program:Next-Generation Therapies
Disease Teams:
Bone Marrow Transplantation
Leukemia and Lymphoma
View Website

Research Interests

  • Neoplasms
  • Terpenes
  • Therapeutics
  • Lovastatin
  • Proteins
  • Prenylation
  • Diphosphonates
  • Leukemia
  • farnesyl pyrophosphate
  • geranylgeranyl pyrophosphate
  • Pharmacokinetics
  • Protein Prenylation

Clinical Trials

Blood and Bone Marrow Collection from Patients with Hematological Malignancies for Study of Anti-Tumor Immunity
Clofarabine followed by Fludarabine, Busulfan, Total-Body Irradiation and Hematopoietic Stem Cell Transplant with Post-Transplant Cyclophosphamide for Non-remission Acute Myeloid Leukemia
A Phase Ib/II Study of Venetoclax (ABT-199) in Combination with Liposomal Vincristine in Patients with Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia

Recent Publications


Bluethmann, SM, Wang, M, Wasserman, E, Chen, C, Zaorsky, NG, Hohl, RJ & McDonald, AC 2020, 'Prostate cancer in Pennsylvania: The role of older age at diagnosis, aggressiveness, and environmental risk factors on treatment and mortality using data from the Pennsylvania Cancer Registry', Cancer medicine, vol. 9, no. 10, pp. 3623-3633.


Huang, X, Sterling, NW, Du, G, Sun, D, Stetter, C, Kong, L, Zhu, Y, Neighbors, J, Lewis, MM, Chen, H, Hohl, RJ & Mailman, RB 2019, 'Brain cholesterol metabolism and Parkinson's disease', Movement Disorders, vol. 34, no. 3, pp. 386-395.
Weissenrieder, JS, Neighbors, JD, Mailman, RB & Hohl, RJ 2019, 'Cancer and the dopamine D2 receptor: A pharmacological perspective', Journal of Pharmacology and Experimental Therapeutics, vol. 370, no. 1, pp. 111-126.
Jia, B, Zhao, C, Rakszawski, KL, Claxton, DF, Christopher Ehmann, W, Rybka, WB, Mineishi, S, Wang, M, Shike, H, Bayerl, MG, Sivik, JM, Schell, TD, Drabick, JJ, Hohl, RJ & Zheng, H 2019, 'Eomes+T-betlow CD8+ T cells are functionally impaired and are associated with poor clinical outcome in patients with acute myeloid leukemia', Cancer Research, vol. 79, no. 7, pp. 1635-1645.
Allen, BG, Bodeker, KL, Smith, MC, Monga, V, Sandhu, S, Hohl, R, Carlisle, T, Brown, H, Hollenbeck, N, Vollstedt, S, Greenlee, JD, Howard, MA, Mapuskar, KA, Seyedin, SN, Caster, JM, Jones, KA, Cullen, JJ, Berg, D, Wagner, BA, Buettner, GR, TenNapel, MJ, Smith, BJ, Spitz, DR & Buatti, JM 2019, 'First-in-human phase I clinical trial of pharmacologic ascorbate combined with radiation and temozolomide for newly diagnosed glioblastoma', Clinical Cancer Research, vol. 25, no. 22, pp. 6590-6597.
Larson-Casey, JL, Vaid, M, Gu, L, He, C, Cai, GQ, Ding, Q, Davis, D, Berryhill, TF, Wilson, LS, Barnes, S, Neighbors, JD, Hohl, RJ, Zimmerman, KA, Yoder, BK, Longhini, ALF, Hanumanthu, VS, Surolia, R, Antony, VB & Brent Carter, A 2019, 'Increased flux through the mevalonate pathway mediates fibrotic repair without injury', Journal of Clinical Investigation, vol. 129, no. 11, pp. 4962-4978.
Zhao, C, Jia, B, Wang, M, Schell, TD, Claxton, DF, Ehmann, WC, Rybka, WB, Mineishi, S, Naik, S, Songdej, N, Sivik, JM, Hohl, RJ, Zeng, H & Zheng, H 2020, 'Multi-dimensional analysis identifies an immune signature predicting response to decitabine treatment in elderly patients with AML', British Journal of Haematology, vol. 188, no. 5, pp. 674-684.
Weissenrieder, JS, Reed, JL, Green, MV, Moldovan, GL, Koubek, EJ, Neighbors, JD & Hohl, RJ 2020, 'The Dopamine D2 Receptor Contributes to the Spheroid Formation Behavior of U87 Glioblastoma Cells', Pharmacology, vol. 105, no. 1-2, pp. 19-27.


Jia, B, Wang, L, Claxton, DF, Ehmann, WC, Rybka, WB, Mineishi, S, Rizvi, S, Shike, H, Bayerl, M, Schell, TD, Hohl, RJ & Zheng, H 2018, 'Bone marrow CD8 T cells express high frequency of PD-1 and exhibit reduced anti-leukemia response in newly diagnosed AML patients', Blood Cancer Journal, vol. 8, no. 3, 34.
Weissenrieder, JS, Reilly, JE, Neighbors, JD & Hohl, RJ 2019, 'Inhibiting geranylgeranyl diphosphate synthesis reduces nuclear androgen receptor signaling and neuroendocrine differentiation in prostate cancer cell models', Prostate, vol. 79, no. 1, pp. 21-30.
Kokolus, KM, Haley, JS, Koubek, EJ, Gowda, R, Dinavahi, SS, Sharma, A, Claxton, DF, Helm, KF, Drabick, JJ, Robertson, GP, Neighbors, JD, Hohl, RJ & Schell, TD 2019, 'Schweinfurthin natural products induce regression of murine melanoma and pair with anti-PD-1 therapy to facilitate durable tumor immunity', OncoImmunology, vol. 8, no. 2, e1539614.
Koubek, EJ, Weissenrieder, JS, Neighbors, JD & Hohl, RJ 2018, 'Schweinfurthins: Lipid Modulators with Promising Anticancer Activity', Lipids, vol. 53, no. 8, pp. 767-784.
Wang, L, Jia, B, Claxton, DF, Ehmann, WC, Rybka, WB, Mineishi, S, Naik, S, Khawaja, MR, Sivik, J, Han, J, Hohl, RJ & Zheng, H 2018, 'VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML', OncoImmunology, vol. 7, no. 9, e1469594.


Zhu, L, Kong, Y, Zhang, J, Claxton, DF, Ehmann, WC, Rybka, WB, Palmisiano, ND, Wang, M, Jia, B, Bayerl, M, Schell, TD, Hohl, RJ, Zeng, H & Zheng, H 2017, 'Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia', Journal of Hematology and Oncology, vol. 10, no. 1, 124.
Lee, JSH, Blumenthal, GM, Hohl, RJ & Huang, SM 2017, 'Cancer Therapy: Shooting for the Moon', Clinical pharmacology and therapeutics, vol. 101, no. 5, pp. 552-558.
Schoenfeld, JD, Sibenaller, ZA, Mapuskar, KA, Wagner, BA, Cramer-Morales, KL, Furqan, M, Sandhu, S, Carlisle, TL, Smith, MC, Abu Hejleh, T, Berg, DJ, Zhang, J, Keech, J, Parekh, KR, Bhatia, S, Monga, V, Bodeker, KL, Ahmann, L, Vollstedt, S, Brown, H, Shanahan Kauffman, EP, Schall, ME, Hohl, RJ, Clamon, GH, Greenlee, JD, Howard, MA, Shultz, MK, Smith, BJ, Riley, DP, Domann, FE, Cullen, JJ, Buettner, GR, Buatti, JM, Spitz, DR & Allen, BG 2017, 'O2⋅− and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate', Cancer Cell, vol. 31, no. 4, pp. 487-500.e8.
Teye, EK, Sido, A, Xin, P, Finnberg, NK, Gokare, P, Kawasawa, YI, Salzberg, AC, Shimko, S, Bayerl, M, Ehmann, WC, Claxton, DF, Rybka, WB, Drabick, JJ, Wang, HG, Abraham, T, El-Deiry, WS, Brodsky, RA, J.Hohl, R & Pu, JJ 2017, 'PIGN gene expression aberration is associated with genomic instability and leukemic progression in acute myeloid leukemia with myelodysplastic features', Oncotarget, vol. 8, no. 18, pp. 29887-29905.
Reilly, JE, Neighbors, JD & Hohl, RJ 2017, 'Targeting protein geranylgeranylation slows tumor development in a murine model of prostate cancer metastasis', Cancer Biology and Therapy, vol. 18, no. 11, pp. 872-882.


Hohl, RJ 2016, 'Anticoagulants: Major Advances Without Clear Consensus', Clinical pharmacology and therapeutics, pp. 116-118.
Ferguson, SD, Xiu, J, Weathers, SP, Zhou, S, Kesari, S, Weiss, SE, Verhaak, RG, Hohl, RJ, Barger, GR, Reddy, SK & Heimberger, AB 2016, 'GBM-associated mutations and altered protein expression are more common in young patients', Oncotarget, vol. 7, no. 43, pp. 69466-69478.
Raje, NS, Faber, EA, Richardson, PG, Schiller, G, Hohl, RJ, Cohen, AD, Forero, A, Carpenter, S, Nguyen, TS, Conti, I, Kaiser, CJ, Cronier, DM, Wooldridge, JE & Anderson, KC 2016, 'Phase 1 study of tabalumab, a human anti-B-cell activating factor antibody, and bortezomib in patients with relapsed/refractory multiple myeloma', Clinical Cancer Research, vol. 22, no. 23, pp. 5688-5695.

Clinical Trials Search

Children (age < 18 years)
Adults (age >= 18 years)